STRM.BIO, a pre-clinical biotechnology company based in Boston, MA, has secured $16.4 million in investment capital. This funding round marks a significant milestone for the company, which is focused on advancing gene therapy through its proprietary extracellular vesicle (EV) platform. STRM.BIO aims to leverage EVs to deliver treatments directly to patients (in vivo), addressing limitations of traditional gene therapy approaches.
The company's approach utilizes extracellular vesicles, which are natural carriers of nucleic acids and proteins. Unlike viral vectors, EVs offer innate targeting capabilities, amenability to large-scale commercial manufacturing, and low immunogenicity. These characteristics position EVs as promising cell messengers for gene therapies, potentially making existing treatments more effective and enabling new therapeutic avenues. STRM.BIO's platform is designed to establish a new class of therapeutics, with the potential to democratize gene therapy.
This capital infusion is crucial for STRM.BIO as it continues to develop its pre-clinical programs. The funds will support ongoing research and development efforts, enabling the company to further validate its EV platform and advance its therapeutic candidates. While specific allocation details were not disclosed, the company plans to use the funds for growth initiatives, including expanding its scientific team and accelerating the progression of its pipeline.
STRM.BIO's mission is to bring hope to patients fighting rare diseases worldwide by making gene therapy more accessible and effective. The company believes its work has the potential to transform the landscape of genetic medicine. With this new investment, STRM.BIO is well-positioned to continue its efforts in establishing its novel EV-based therapeutics and moving closer to its vision of delivering life-saving realities for patients.
